Linked Life Data

11983866

Source:http://linkedlifedata.com/resource/pubmed/id/11983866

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2002-5-15
pubmed:abstractText
An important goal of cancer immunology is the identification of antigens associated with tumor destruction. Vaccination with irradiated tumor cells engineered to secrete granulocyte/macrophage colony-stimulating factor (GM-CSF) generates potent, specific, and long-lasting antitumor immunity in multiple murine tumor models. A phase I clinical trial of this vaccination strategy in patients with advanced melanoma demonstrated the consistent induction of dense CD4(+) and CD8(+) T lymphocyte and plasma cell infiltrates in distant metastases, resulting in extensive tumor destruction, fibrosis, and edema. Antimelanoma antibody and cytotoxic T cell responses were associated with tumor cell death. To characterize the targets of these responses, we screened an autologous cDNA expression library prepared from a densely infiltrated metastasis with postvaccination sera from a long-term responding patient. High-titer IgG antibodies detected ATP6S1, a putative accessory unit of the vacuolar H(+)-ATPase complex. A longitudinal analysis of this patient revealed an association between the vaccine-induced increase in antibodies to ATP6S1 and tumor destruction. Three additional vaccinated melanoma patients and three metastatic non-small cell lung carcinoma patients vaccinated with autologous GM-CSF-secreting tumor cells similarly showed a correlation between humoral responses to ATP6S1 and tumor destruction. Moreover, a chronic myelogenous leukemia patient who experienced a complete remission after CD4(+) donor lymphocyte infusions also developed high-titer antibodies to ATP6S1. Lastly, vaccination with GM-CSF-secreting B16 melanoma cells stimulated high-titer antibodies to ATPS1 in a murine model. Taken together, these findings demonstrate that potent humoral responses to ATP6S1 are associated with immune-mediated destruction of diverse tumors.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10064075, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10064076, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10336633, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10508479, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10514004, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10587362, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10777660, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10781081, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10866317, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10951226, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-10974024, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-11027314, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-11104805, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-11221874, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-11259659, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-11416219, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-11606714, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-11724951, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-1840703, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-7513904, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-7593290, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-7929063, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-8006576, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-8022805, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-8097319, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-8113668, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-8642276, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-8961292, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-8962137, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-9435247, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-9497340, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-9500606, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-9573003, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-9610721, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-9739073, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-9789055, http://linkedlifedata.com/resource/pubmed/commentcorrection/11983866-9935203
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
14
pubmed:volume
99
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6919-24
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
pubmed:affiliation
Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't